ClinicalTrials.gg
CompletedNCT01836523ADJUNCT ONE™Updated Mar 6, 2017Results posted

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 182 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-06.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,398
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.

Enrollment
Largest of 32
1,398 · median 38
Started
2013
with 4 others
Phase 3
9 of 32
none open now
Registered
11th of 32
by date
Lead sponsor
5 of 32
Novo Nordisk A/S

Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 5 that started in 2013, is one of 9 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing liraglutide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 1,398 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • obtained
    • Type 1 diabetes mellitus for 12 months or longer
    • Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump) treatment for 6 months or longer
    • Stable insulin treatment for the last 3 months prior to Screening, as judged and documented by the investigator
    • 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive, (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))
    • Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, complete trial related questionnaires, diaries, self-monitoring of plasma glucose, self titration of insulin and attend all scheduled visits

Exclusion criteria

Exclusion Criteria:

    • Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPP-4) inhibitors
    • Use of any medication, which in the investigator's opinion could interfere with the glycaemic control or affect the subject's safety.Premix insulin is not allowed
    • Known proliferative retinopathy or maculopathy requiring acute treatment
    • Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator
    • Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or above 100 mmHg for diastolic
    • History of acute or chronic pancreatitis
    • Screening calcitonin value equal to or above 50 ng/L
    • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)
    • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,398 participants (actual)

Study arms

  • Experimental
    Liraglutide 0.6 mg + insulin

    Drug: liraglutide

  • Experimental
    Liraglutide 1.2 mg + insulin

    Drug: liraglutide

  • Experimental
    Liraglutide 1.8 mg + insulin

    Drug: liraglutide

  • Placebo comparator
    Liraglutide placebo 0.6 mg + insulin

    Drug: placebo

  • Placebo comparator
    Liraglutide placebo 1.2 mg + insulin

    Drug: placebo

  • Placebo comparator
    Liraglutide placebo 1.8 mg + insulin

    Drug: placebo

Interventions

  • Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).

    Time frame: Week 0, week 52

  2. Change From Baseline in Body Weight

    Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.

    Time frame: Week 0, week 52

  3. Change From Baseline in Total Daily Insulin Dose

    Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.

    Time frame: Week 0, week 52

Secondary outcomes

  1. Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes

    This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of \<3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.

    Time frame: Weeks 0-52

08

Results

Posted Mar 6, 2017

Participant flow

The trial was conducted at 177 sites in 17 countries: Argentina: 6, Australia: 5, Belgium: 4, Canada: 14, Germany: 8, Finland: 6, France: 13, United Kingdom: 10, Ireland: 5, Israel: 6, Netherlands: 6, Norway: 5, Poland: 5, Russia: 5, Sweden: 4, Ukraine: 5, United States: 70

Participant flow — Overall Study
MilestoneLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Started351350349348
Exposed350348347348
Completed300265258274
Not completed51859174
Withdrew: Adverse event15414914
Withdrew: Protocol violation6324
Withdrew: Met withdrawal criteria13132127
Withdrew: Unclassified17281929

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).

Time frame:
Week 0, week 52
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Change From Baseline in HbA1c (Glycosylated Haemoglobin)-0.45 ± 0.741-0.50 ± 0.767-0.54 ± 0.729-0.34 ± 0.707
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Treatment difference: -0.20 · 95% CI -0.32 to -0.07
  • Liraglutide 1.2 mg vs Placebo · Treatment difference: -0.15 · 95% CI -0.27 to -0.03
  • Liraglutide 0.6 mg vs Placebo · Treatment difference: -0.09 · 95% CI -0.21 to 0.03
PrimaryChange From Baseline in Body Weight

Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.

Time frame:
Week 0, week 52
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Change From Baseline in Body Weight-1.34 ± 4.183-2.73 ± 4.524-4.02 ± 4.8730.94 ± 3.828
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Treatment difference: -4.90 · 95% CI -5.65 to -4.16
  • Liraglutide 1.2 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Treatment difference: -3.55 · 95% CI -4.29 to -2.81
  • Liraglutide 0.6 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Treatment difference: -2.19 · 95% CI -2.91 to -1.47
PrimaryChange From Baseline in Total Daily Insulin Dose

Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Change From Baseline in Total Daily Insulin Dose
ratioLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Change From Baseline in Total Daily Insulin Dose1.04 ± 23.750.98 ± 26.660.95 ± 24.211.04 ± 26.69
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Treatment ratio: 0.92 · 95% CI 0.88 to 0.96
  • Liraglutide 1.2 mg vs Placebo · Mixed Models Analysis · p = 0.0148 · Treatment ratio: 0.95 · 95% CI 0.91 to 0.99
  • Liraglutide 0.6 mg vs Placebo · Mixed Models Analysis · p = 0.9615 · Treatment ratio: 1.00 · 95% CI 0.96 to 1.04
SecondaryNumber of Treatment-emergent Symptomatic Hypoglycaemic Episodes

This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of \<3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.

Time frame:
Weeks 0-52
Reported as:
Number · episodes
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes
episodesLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes4954460246143654
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Negative binomial regression · p = 0.0081 · Rate ratio: 1.31 · 95% CI 1.07 to 1.59
  • Liraglutide 1.2 mg vs Placebo · Negative binomial regression · p = 0.0219 · Rate ratio: 1.27 · 95% CI 1.03 to 1.55
  • Liraglutide 0.6 mg vs Placebo · Negative binomial regression · p = 0.1079 · Rate ratio: 1.17 · 95% CI 0.97 to 1.43

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 0.6 mg—35/350 (10%)259/350 (74%)
Liraglutide 1.2 mg—36/348 (10.3%)263/348 (75.6%)
Liraglutide 1.8 mg—29/347 (8.4%)282/347 (81.3%)
Placebo—38/348 (10.9%)224/348 (64.4%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
HypoglycaemiaMetabolism and nutrition disorders3/3507/3485/34713/348
Hypoglycaemic unconsciousnessNervous system disorders5/3503/3486/3476/348
Urinary tract infectionInfections and infestations0/3500/3483/3470/348
Diabetic ketoacidosisMetabolism and nutrition disorders3/3501/3483/3470/348
HyperglycaemiaMetabolism and nutrition disorders3/3503/3483/3472/348
AppendicitisInfections and infestations0/3501/3480/3472/348
Macular oedemaEye disorders0/3500/3481/3470/348
DysphagiaGastrointestinal disorders0/3500/3481/3470/348
AbscessInfections and infestations0/3500/3481/3470/348
Abscess limbInfections and infestations0/3500/3481/3470/348
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlacebo
NauseaGastrointestinal disorders112/350141/348172/34742/348
NasopharyngitisInfections and infestations105/35081/34883/34785/348
DiarrhoeaGastrointestinal disorders41/35050/34864/34738/348
VomitingGastrointestinal disorders24/35044/34864/34721/348
Decreased appetiteMetabolism and nutrition disorders31/35043/34864/3476/348
HeadacheNervous system disorders56/35046/34849/34740/348
Upper respiratory tract infectionInfections and infestations33/35023/34843/34740/348
DyspepsiaGastrointestinal disorders26/35027/34838/3478/348
Abdominal painGastrointestinal disorders20/35016/34829/3478/348
GastroenteritisInfections and infestations21/35015/34829/34715/348

Baseline characteristics

Full analysis set (FAS) included all randomised subjects who received at least one dose and had any post-randomisation data. Five subjects, who started the study, were excluded because of no exposure to study drug and 4 subjects were excluded because of non-availability of post-baseline data.

Age, Continuous
Age, Continuous(years)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Mean43.6 ± 12.7843.9 ± 13.0643.7 ± 13.3343.4 ± 12.5743.7 ± 12.93
Gender
Gender(Participants)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Female186179181180726
Male164167165167663
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Mean8.18 ± 0.7388.16 ± 0.7798.14 ± 0.7408.15 ± 0.7288.16 ± 0.746
Body weight
Body weight(kg)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Mean86.54 ± 17.33885.39 ± 17.21086.27 ± 17.32186.41 ± 17.76886.15 ± 17.397
Total daily actual insulin dose-continuous subcutaneous insulin infusion
Total daily actual insulin dose-continuous subcutaneous insulin infusion(units)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Geometric mean52.97 (13.8 to 137.1)50.73 (19.7 to 160.5)50.46 (8.7 to 150.2)49.18 (3.9 to 176.1)50.65 (3.9 to 176.1)
Total daily actual insulin dose - Multiple daily injections
Total daily actual insulin dose - Multiple daily injections(units)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgPlaceboTotal
Geometric mean59.54 (22.9 to 181.6)59.61 (16 to 282.5)62.52 (16.4 to 271.3)62.42 (20.3 to 230)60.94 (16 to 282.5)
09

Study locations

182 sites
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92648, United States
  • Novo Nordisk Investigational Site
    La Mesa, California 91942, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80209, United States
  • Novo Nordisk Investigational Site
    Ft. Lauderdale, Florida 33312, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33619, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30308-2253, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Marietta, Georgia 30060, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Savannah, Georgia 31405, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Metarie, Louisiana 70006, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Springfield, Missouri 65807, United States
  • Novo Nordisk Investigational Site
    St. Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63110-1020, United States
  • Novo Nordisk Investigational Site
    St. Peters, Missouri 63376, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Butte, Montana 59701, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Mineola, New York 11501, United States
  • Novo Nordisk Investigational Site
    New York, New York 10029, United States
  • Novo Nordisk Investigational Site
    New York, New York 10032, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Syracuse, New York 13210, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Mentor, Ohio 44060, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224-2215, United States
  • Novo Nordisk Investigational Site
    Upper Darby, Pennsylvania 19082, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Novo Nordisk Investigational Site
    Summerville, South Carolina 29485, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404-1192, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119-3821, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37212, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    El Paso, Texas 79912, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84102, United States
  • Novo Nordisk Investigational Site
    Bennington, Vermont 05201, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23510, United States
  • Novo Nordisk Investigational Site
    Federal Way, Washington 98003, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99208, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Novo Nordisk Investigational Site
    Caba, C1118AAT, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1440AAD, Argentina
  • Novo Nordisk Investigational Site
    Capital Federal, 1405, Argentina
  • Novo Nordisk Investigational Site
    Córdoba, X5016KEH, Argentina
  • Novo Nordisk Investigational Site
    Mendoza, 5500, Argentina
  • Novo Nordisk Investigational Site
    Morón, B1708IFF, Argentina
  • Novo Nordisk Investigational Site
    Broadmeadow, New South Wales 2292, Australia
  • Novo Nordisk Investigational Site
    Elizabeth Vale, South Australia 5112, Australia
  • Novo Nordisk Investigational Site
    Keswick, South Australia 5035, Australia
  • Novo Nordisk Investigational Site
    Melbourne, Victoria 3004, Australia
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3050, Australia
  • Novo Nordisk Investigational Site
    Arlon, 6700, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Liège, 4000, Belgium
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2E1, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Novo Nordisk Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • Novo Nordisk Investigational Site
    Cambridge, Ontario N1R 7L6, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6A 4V2, Canada
  • Novo Nordisk Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • Novo Nordisk Investigational Site
    Oakville, Ontario L6M 1M1, Canada
  • Novo Nordisk Investigational Site
    Thornhill, Ontario L4J 8L7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5T 3L9, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H2W 1R7, Canada
  • Novo Nordisk Investigational Site
    Sherbrooke, Quebec J1G 5K2, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G2, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G5, Canada

Showing the first 100 of 182 sites across 17 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9. PubMed 27506222 ↗
  • Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Erratum In: Diabetes Obes Metab. 2022 Nov;24(11):2280. doi: 10.1111/dom.14846. PubMed 34463425 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2013
First posted
Apr 22, 2013
Start
Nov 2013
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Mar 6, 2017
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01836523
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 22, 2013
Start date
Nov 2013
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Mar 6, 2017
Last update
Mar 6, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion